GSK plc (LON:GSK) Receives GBX 1,842.50 Average Target Price from Brokerages

GSK plc (LON:GSK) has received an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 1,842.50 ($23.36).

Several equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a GBX 1,850 ($23.45) price target on shares of GSK in a research report on Tuesday, September 3rd. Shore Capital reaffirmed a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,820 ($23.07) price target on shares of GSK in a research report on Tuesday, September 10th.

GSK Stock Performance

The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The stock has a market capitalization of £54.84 billion, a P/E ratio of 1,184.07, a P/E/G ratio of 1.24 and a beta of 0.31. The business’s 50 day moving average is GBX 1,449.02 and its 200-day moving average is GBX 1,558.36. GSK has a fifty-two week low of GBX 1,282.50 ($16.26) and a fifty-two week high of GBX 1,823.50 ($23.12).

GSK Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be issued a GBX 15 ($0.19) dividend. The ex-dividend date is Thursday, November 14th. This represents a dividend yield of 1.03%. GSK’s dividend payout ratio (DPR) is presently 5,309.73%.

Insider Buying and Selling

In related news, insider Jonathan Symonds bought 7,150 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of GBX 1,394 ($17.67) per share, for a total transaction of £99,671 ($126,357.76). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of GSK stock in a transaction dated Monday, September 23rd. The shares were acquired at an average price of GBX 2,051 ($26.00) per share, with a total value of £9,147.46 ($11,596.68). Insiders have bought a total of 7,604 shares of company stock valued at $10,893,038 in the last quarter. Company insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.